Antibody · 난소암

57개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved57 programs
AntibodyLimited DatastalePENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#Popular#monoclonal-antibody+4
Trials 143Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
AntibodyCurated CorestaleBristol Myers SquibbPhase 2

Relatlimab (Relatlimab)

Various Advanced Cancer · FRα

#FR#Antibody#Phase2#BioJungboMoa-pick#Popular+4
Trials 74Status Recruiting
AntibodyLimited DatastaleRegeneronPhase 2

Cemiplimab + Fianlimab [Fixed Dose Combination (FDC, Cemiplimab + Fianlimab [Fixed Dose Combination, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)])

Ovarian Cancer; Fallopian Tube Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 59Status Recruiting
AntibodyCurated CorestalePfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#BioJungboMoa-pick#Popular+4
Trials 54Status Recruiting
AntibodyLimited DatastalePfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 51Status Active
AntibodyCurated CorestaleEpizyme, Inc.Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 49Status Recruiting
AntibodyCurated CorestaleJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 40Status Discontinued
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#monoclonal-antibody#OvarianCancer+3
Trials 39Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 3

H1 receptor antagonist (H1 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#monoclonal-antibody#OvarianCancer+3
Trials 31Status Recruiting
AntibodyLimited DatastaleMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#monoclonal-antibody#OvarianCancer+2
Trials 31Status Recruiting
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, Administration of ceralasertib and durvalumab)

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer · Adv Solid Malig - H&N SCC, ATM Pro / Def

#AdvSolidMalig-HNSCCATMProDef#Antibody#Phase1#monoclonal-antibody#AdvSolidMalig-HNSCC+3
Trials 12Status Recruiting
AntibodyLimited DatastaleARCAGYPhase 2

Ubamatamab (Ubamatamab)

Ovarian Cancer · Recurrent Ovarian Cancer

#RecurrentOvarianCancer#Antibody#Phase2#monoclonal-antibody#OvarianCancer+1
Trials 7Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 6Status Discontinued
AntibodyLimited DatastaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#monoclonal-antibody#OvarianCancer+2
Trials 5Status Discontinued
AntibodyLimited DatastaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 4Status Active
AntibodyCurated CorestaleSutro Biopharma, Inc.Phase 3

Luveltamab tazevibulin (Luveltamab tazevibulin)

Ovarian Cancer; Epithelial Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+2
Trials 3Status Discontinued
AntibodyLimited DatastaleJanssenPhase 1

daratumumab (Darzalex, Actinium Ac 225-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 2Status Recruiting
AntibodyLimited DatastaleJanssenPhase 1

daratumumab (Darzalex, Indium In 111-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 2Status Recruiting

1 / 3 pages

← PreviousNext →